Comparative Efficacy of Early COVID-19 Monoclonal Antibody Therapies: A Retrospective Analysis

BACKGROUND: Bamlanivimab and casirivimab/imdevimab are monoclonal antibody (mAb) treatments used for mild to moderate coronavirus disease 2019 (COVID-19) in high-risk patients. To date, there are few data summarizing real-world evidence comparing the 2 mAbs. Additionally, there are insufficient data...

Descripción completa

Detalles Bibliográficos
Autores principales: San Filippo, Savanna, Crovetto, Brynna, Bucek, John, Nahass, Ronald G, Milano, Marc, Brunetti, Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923391/
https://www.ncbi.nlm.nih.gov/pubmed/35299987
http://dx.doi.org/10.1093/ofid/ofac080

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923391/
https://www.ncbi.nlm.nih.gov/pubmed/35299987
http://dx.doi.org/10.1093/ofid/ofac080

Ejemplares similares